Boron-Containing Compounds: Identification, Synthesis, Biological Actions and Pharmacology

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1108

Special Issue Editors


E-Mail Website
Guest Editor
Laboratorio de Neurofisiología, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Mexico City 11340, Mexico
Interests: boron; medicinal chemistry; drug design; GPCR; human physiology
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Department of Pharmacognosy, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 2 Petru Rareş Street, 200349 Craiova, Romania
Interests: natural products chemistry; boron containing compounds; chromatography; bioactivity analysis

Special Issue Information

Dear Colleagues,

Boron-containing compounds (BCCs) are gaining increasing attention in drug development due to their promising therapeutic potential. Currently, five BCCs—bortezomib, tavaborole, ixazomib, crisaborole, and vaborbactam—have been successfully developed into marketed drugs. Additionally, naturally occurring BCCs, such as boric acid, sodium tetraborate, and fructoborate, have shown bioactivity and have been proposed as pharmacophores for various medical applications. While many BCCs have been predominantly explored for their antimicrobial and anticancer properties, emerging research suggests they may hold therapeutic potential across a wider range of biomedical fields.

This Special Issue aims to highlight and compile new research on BCCs, whether discovered in nature or synthesized in the laboratory. We welcome studies focusing on the chemistry and bioactivity of these compounds, as well as investigations into their pharmacological (pharmacodynamics/pharmacokinetics) profiles, including those already in clinical use. We are also interested in medicinal chemistry studies involving BCCs, including but not limited to the design of novel formulations, biomaterials, and compounds with potential applications in the prevention, diagnosis, or treatment of diseases.

This Special Issue will serve as a platform to highlight recent advancements in the medicinal chemistry of boron-containing compounds and their evolving role in addressing unmet medical needs.

We look forward to your valuable contributions to this exciting and rapidly growing field.

Dr. Marvin Antonio Soriano-Ursúa
Dr. Andrei Biță
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • boron
  • drug development
  • drug discovery
  • bioactive boron compounds
  • bioinorganic chemistry
  • inorganic biological chemistry
  • synthesis
  • natural boron compounds
  • chemical characterization

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 7660 KiB  
Article
Boric Acid Protects the Uterus and Fallopian Tubes from Cyclophosphamide-Induced Toxicity in a Rat Model
by Enes Karaman and Adem Yavuz
Pharmaceuticals 2024, 17(12), 1716; https://doi.org/10.3390/ph17121716 - 19 Dec 2024
Viewed by 775
Abstract
Background/Objectives: Cyclophosphamide (CP) is widely used for treating various cancers and autoimmune diseases, but it causes damage to reproductive organs due to oxidative stress (OS) and inflammation. Boric acid (BA) has antioxidant properties that may help reduce OS, which is critical for [...] Read more.
Background/Objectives: Cyclophosphamide (CP) is widely used for treating various cancers and autoimmune diseases, but it causes damage to reproductive organs due to oxidative stress (OS) and inflammation. Boric acid (BA) has antioxidant properties that may help reduce OS, which is critical for preserving uterine functionality, particularly for cancer patients considering pregnancy after cryopreservation. This study aimed to determine whether BA could diminish CP-induced toxicity in the uterus and fallopian tubes (FT) using CP-induced toxicity in a rat model. Methods: Forty female Wistar rats, aged 18–20 weeks, were divided into four groups as follows: control, oral BA (OBR), CP, and CP plus OBR (CP + OBR). The toxicity was induced in the CP and CP + OBR groups with an initial dose of 200 mg/kg CP, followed by 8 mg/kg daily for 14 days. Rats in the OBR and CP + OBR groups received 20 mg/kg/day of BA. After the 16-day experiment, tissues were collected for analysis. Results: Histopathological and immunohistochemical assessments of IL-6 and HIF-1α expressions were used to evaluate inflammation and OS. The control, OBR, and CP + OBR groups maintained normal tissue features, while the CP group showed epithelial cell shedding, vacuolization, degenerative endometrial glands, lymphocyte infiltration, and reduced collagen fiber density. Elevated HIF-1α and IL-6 expressions in the uterus and FT indicated significant OS and inflammation. Conclusions: The study concluded that BA supplementation in CP-treated rats effectively reduced CP-induced uterine and FT damage, suggesting the potential protective role of BA in managing CP-associated toxicity. Full article
Show Figures

Graphical abstract

Back to TopTop